Drug Trial Radar · NCT05834543
Clinical Trial to Evaluate the Safety and Effectiveness of TQB2618 Injection Combined Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma
Last checked: Nov 19, 2026Latest source record: Jul 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
34
Actual
Start
May 26, 2023
Primary completion
Oct 23, 2024
Study completion Mar 3, 2025
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 28, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To investigate the efficacy and safety of TQB2618 injection combined Penpulimab and chemotherapy in the first-line treatment of recurrent/metastatic esophageal squamous cell carcinoma compared with Penpulimab combined chemotherapy. The primary efficacy outcomes are progression free survival (PFS) and objective response rate (ORR).
Conditions
- Advanced Esophageal Squamous Cell Carcinoma
Interventions
TQB2618 injection, Penpulimab injection, Paclitaxel, CisplatinDrug
TQB2618 injection:Anti-TIM-3 monoclonal antibody. Penpulimab injection:Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1). Paclitaxel and Cisplatin are chemotherapy.
Penpulimab injection, Paclitaxel, CisplatinDrug
Penpulimab injection:Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1). Paclitaxel and Cisplatin are chemotherapy.
TQB2618 injection, Penpulimab injection, TQB3617capsulesDrug
TQB2618 injection:Anti-TIM-3 monoclonal antibody. Penpulimab injection:Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1).
Primary outcomes
What the sponsor says the trial is designed to measure.
- PFSTime frame: Baseline up to two years.
- ORRTime frame: Baseline up to two years.
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Tongling People's Hospital
Tongling, Anhui, China
The First Affiliated Hospital of Wannan Medical College
Wuhu, Anhui, China
AnYang Tumor Hospital
Anyang, Henan, China
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Zhumadian Central Hospital
Zhumadian, Henan, China
Affiliated Hospital of Jining Medical College
Jining, Shandong, China
Changzhi People's Hospital
Changzhi, Shanxi, China
Heping Hospital Affiliated to Changzhi Medical College
Changzhi, Shanxi, China
Jincheng General Hospital
Jincheng, Shanxi, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.